Flagship Pioneering

Flagship Pioneering and Metaphore Biotechnologies Announce Research Collaboration with Novo Nordisk to Develop Next-Generation Therapeutics for Obesity Management

Retrieved on: 
목요일, 5월 9, 2024
Flagship Pioneering, Machine learning, Partnership, Research, Flagship, Obesity, Disease, Therapy, Novo Nordisk, Panasonic Executive Partner, Molecular mimicry, Biology, Drug development, MIMIC

CAMBRIDGE, Mass., May 9, 2024 /PRNewswire/ -- Metaphore Biotechnologies, a Flagship-founded biotechnology company designing novel therapeutics by combining machine learning and molecular mimicry, today joined Flagship Pioneering in announcing a research collaboration with Novo Nordisk to develop up to two next-generation therapeutics for obesity management.

Key Points: 
  • The collaboration is signed under the broader strategic partnership between Novo Nordisk and Flagship Pioneering to develop a portfolio of novel treatment approaches for cardiometabolic and rare diseases.
  • Metaphore will work jointly with Pioneering Medicines and Novo Nordisk to advance the programs through foundational activities and preclinical development, after which point Novo Nordisk could advance the programs into clinical studies.
  • Metaphore is the third Flagship-founded company to advance research programs under the strategic partnership between Novo Nordisk and Flagship Pioneering following programs with Omega Therapeutics and Cellarity which were announced earlier this year.
  • Novo Nordisk will also reimburse R&D costs and participate in a future financing round for Metaphore.

Ring Therapeutics Presents New Data on Anellogy™ Platform at the 27th Annual American Society of Gene & Cell Therapy Conference

Retrieved on: 
화요일, 5월 7, 2024
Commensalism, AMD, Flagship Pioneering, Tropism, MD, Cell, AAV, Eye, Potential, Real-time, Human, DNA, Patient, Gene, Immune system, ANV, MBA, NHP, Therapy, Vaccine

CAMBRIDGE, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Ring Therapeutics, a life sciences company founded by Flagship Pioneering to revolutionize genetic medicines with its commensal virome platform, today announced new preclinical data demonstrating successful transduction and redosability of its Anellovector within non-human primates, as well as expanded payload capacity for the vector beyond the natural genome size of anelloviruses (ANV). The data, which will be presented as one oral presentation and two posters at the 27th Annual America Society of Gene & Cell Therapy (ASGCT) conference, showcases the viability of Anellovectors as the next generation of viral vectors.

Key Points: 
  • The data, which will be presented as one oral presentation and two posters at the 27th Annual America Society of Gene & Cell Therapy (ASGCT) conference, showcases the viability of Anellovectors as the next generation of viral vectors.
  • Additionally, the expanded payload capacity of Anellovectors widens the therapeutic potential of this novel vector class allowing even more patients to be potentially treated.
  • Unlike AAV, which appears to exhibit a strict packaging limit, Anellovectors allow for the packaging of genomes larger than the wild-type genome.
  • A combination of qPCR and next-generation sequencing was used to verify that the encapsidated expanded cargo DNA is intact, circular, and single-stranded.

Cellarity Appoints Head of Platform to Advance Vision for Novel Drug Creation

Retrieved on: 
화요일, 5월 7, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Health Technology, Sickle cell disease, University, Flagship Pioneering, SCD, Machine learning, Life, IND, Novo Nordisk, Chemistry, Biology, Pharming, Multimedia, Drug development, Genomics, Drug discovery, MASH, Head, Pharmaceutical industry

In this role, Woelk will lead Cellarity’s revolutionary platform to create drugs that are presently out of reach with traditional methods of drug discovery.

Key Points: 
  • In this role, Woelk will lead Cellarity’s revolutionary platform to create drugs that are presently out of reach with traditional methods of drug discovery.
  • The Cellarity platform uses proprietary AI models to link biology and chemistry with high-dimensional multi-omic data to uncover novel actionable insights into disease biology and create non-intuitive drug candidates in a vast array of clinical conditions.
  • “Topher’s experience is particularly relevant to Cellarity as we continue to invest in our platform.
  • “I look forward to helping advance the platform by bringing to life insights that will open up opportunities for new drug development programs and help accelerate the company’s pipeline towards the clinic.”

Flagship Pioneering Unveils Prologue Medicines to Unlock the Therapeutic Potential of the Viral Proteome

Retrieved on: 
화요일, 5월 7, 2024
Health, Other Science, Research, Pharmaceutical, Science, Biotechnology, Doctor of Philosophy, Protein, Flagship Pioneering, Viral, Machine learning, Proteome, Entrepreneurship, Disease, Physiology, Virus, Database, MBA, Strategy, Vaccine

Flagship Pioneering, the bioplatform innovation company, today unveiled Prologue Medicines, a company unlocking the therapeutic potential of the viral proteome for the creation of powerful new medicines.

Key Points: 
  • Flagship Pioneering, the bioplatform innovation company, today unveiled Prologue Medicines, a company unlocking the therapeutic potential of the viral proteome for the creation of powerful new medicines.
  • "We asked, what if we could expand beyond the functional boundaries of the human proteome by harnessing viral evolution,” said Noubar Afeyan, Ph.D., Founder and CEO of Flagship Pioneering and Co-Founder and Chairman of the Strategic Oversight Board of Prologue.
  • “By exploring the viral proteome, we can discover novel proteins with enhanced or completely unique therapeutic properties to develop medicines for optimal patient outcomes.”
    Prologue is unlocking viral proteome-assisted drug discovery with its novel DELVE Platform.
  • “The viral proteome dwarfs the human proteome by orders of magnitude, enabling us to reveal a trove of powerful new proteins that can be used as medicines across nearly any therapeutic area,” said Lovisa Afzelius, Ph.D., MBA, Co-Founder and CEO of Prologue and Origination Partner at Flagship Pioneering.

Alltrna Applies Machine Learning to Engineer tRNA Oligonucleotides with Significantly Improved Activity and Demonstrates In Vivo Readthrough of the Two Most Common Premature Termination Codons in Genetic Disease

Retrieved on: 
화요일, 5월 7, 2024
Small RNA, Mutation, Flagship Pioneering, LNP, Machine learning, RNA, Cell, Molecular biology, Computation, Disease, Oligonucleotide, Therapy, Gene, Society, Biology, Annual general meeting, PTC

"The data demonstrate the power of Alltrna's platform to identify key combinations of tRNA sequences and modifications and precisely design tRNA oligonucleotides with significantly improved in vivo activity.

Key Points: 
  • "The data demonstrate the power of Alltrna's platform to identify key combinations of tRNA sequences and modifications and precisely design tRNA oligonucleotides with significantly improved in vivo activity.
  • With optimized engineered tRNAs for the two most prevalent premature termination codons, we are advancing preclinical studies for our first Stop Codon Disease indications."
  • Delivered using a liver-directed lipid nanoparticle (LNP), both optimized tRNAs showed robust in vivo activity in two transgenic mouse models.
  • "We've also demonstrated that we can engineer robust tRNA activity for two different premature termination codons, each of which are highly prevalent in Stop Codon Disease."

Repertoire® Immune Medicines and Bristol Myers Squibb Announce Multi-Year Strategic Collaboration to Develop Tolerizing Vaccines for Autoimmune Diseases

Retrieved on: 
월요일, 4월 29, 2024
Doctor of Philosophy, Flagship Pioneering, BMY, Epitope, Research, Vaccine, Repertoire, Disease, Autoimmune disease, Patient, Immunology, BMS, Immune system, Bristol Myers Squibb, TCR, Biotechnology, Pharmaceutical industry

CAMBRIDGE, Mass., April 29, 2024 /PRNewswire/ -- Repertoire® Immune Medicines, a biotechnology company pioneering the discovery and development of programmable T cell targeted immune medicines, announced today that it has entered a multi-year strategic collaboration with Bristol Myers Squibb (NYSE: BMY) to develop tolerizing vaccines for up to three autoimmune diseases. The collaboration aims to develop efficacious, selective, and durable treatments for patients suffering from autoimmune disease by resetting the immune system.

Key Points: 
  • CAMBRIDGE, Mass., April 29, 2024 /PRNewswire/ -- Repertoire® Immune Medicines, a biotechnology company pioneering the discovery and development of programmable T cell targeted immune medicines, announced today that it has entered a multi-year strategic collaboration with Bristol Myers Squibb (NYSE: BMY) to develop tolerizing vaccines for up to three autoimmune diseases.
  • The collaboration aims to develop efficacious, selective, and durable treatments for patients suffering from autoimmune disease by resetting the immune system.
  • "We are excited to collaborate with Bristol Myers Squibb to combine their leadership in immunology with our unique ability to discover key disease-associated epitopes in patients with autoimmune diseases.
  • This collaboration enables us to serve patients suffering from autoimmune diseases by translating our DECODE discoveries into potentially transformative medicines that address the underlying cause of their disease."

Ring Therapeutics Announces Presentations at the 27th Annual American Society of Gene and Cell Therapy

Retrieved on: 
월요일, 4월 22, 2024
Tropism, Therapy, Flagship Pioneering, Baltimore Convention Center, Gene, Society, Cell, Conference, Vaccine

CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Ring Therapeutics, a life sciences company founded by Flagship Pioneering to revolutionize genetic medicines with its commensal virome platform, today announced an oral presentation and two poster presentations at the 27th Annual American Society of Gene & Cell Therapy (ASGCT) Conference, to be held in Baltimore, Maryland from May 7 – 11, 2024. These presentations showcase the immense promise of a new class of viral vectors from Ring’s Anellogy™ platform to overcome some of the largest barriers associated with delivery of current genetic medicines including redosability and tissue tropism.

Key Points: 
  • CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Ring Therapeutics , a life sciences company founded by Flagship Pioneering to revolutionize genetic medicines with its commensal virome platform, today announced an oral presentation and two poster presentations at the 27th Annual American Society of Gene & Cell Therapy (ASGCT) Conference, to be held in Baltimore, Maryland from May 7 – 11, 2024.
  • These presentations showcase the immense promise of a new class of viral vectors from Ring’s Anellogy™ platform to overcome some of the largest barriers associated with delivery of current genetic medicines including redosability and tissue tropism.
  • Session Title and Location: Emerging Viral Vectors – Ballroom 4, Baltimore Convention Center

Generate:Biomedicines Expands C-suite with Chief Corporate Affairs Officer and Chief Technical Operations Officer

Retrieved on: 
화요일, 4월 30, 2024
Science, Biotechnology, Research, Pharmaceutical, Health, Artificial Intelligence, Health Technology, Technology, Biomedicine, Flagship Pioneering, Woman, Public policy, Digital, White, Senior, Medicine, Multimedia, Biology, Drug discovery, Management

Generate:Biomedicines today announces two key appointments, welcoming Kimberly (Kym) White as the new Chief Corporate Affairs Officer and announcing the promotion of Lisa Wyman to Chief Technical Operations Officer.

Key Points: 
  • Generate:Biomedicines today announces two key appointments, welcoming Kimberly (Kym) White as the new Chief Corporate Affairs Officer and announcing the promotion of Lisa Wyman to Chief Technical Operations Officer.
  • As Chief Corporate Affairs Officer, her expertise in healthcare communications will be pivotal in articulating the company's mission and in driving forward initiatives that showcase the innovative work being done in the field of generative biology.
  • Lisa Wyman, previously the Senior Vice President of Technical Operations, has been promoted to Chief Technical Operations Officer, with an expanded role that now includes leading the company's Digital organization.
  • Together, they will propel us toward our mission to program biology to transform how medicines are created, developed, and accessed.”

Black Diamond Therapeutics Announces Changes to Board of Directors

Retrieved on: 
목요일, 4월 11, 2024
Diamond, Bayer, University, Executive, Ithaca College, University of Pennsylvania, Flagship Pioneering, Scripps Research, Pharmacia, Harvard Business School, Novartis, Therapy, Abbott Laboratories, IMD, Patient, Medicinal chemistry, Immunology, Takeda Oncology, EGFR, Cancer, NSCLC, Partnership, Management

The Company also announced that Wendy Dixon, Ph.D., and Alex Mayweg, Ph.D., have stepped down as members of its Board of Directors.

Key Points: 
  • The Company also announced that Wendy Dixon, Ph.D., and Alex Mayweg, Ph.D., have stepped down as members of its Board of Directors.
  • “On behalf of the board, I am excited to welcome Shannon and Prakash, both seasoned executives who bring deep and highly relevant oncology expertise to our board as we advance BDTX-1535, a potential first and best-in-class fourth-generation EGFR inhibitor,” said Mark Velleca, M.D., Ph.D., Chief Executive Officer of Black Diamond Therapeutics.
  • He currently serves as Chief Executive Officer of a stealth biopharma company working on novel protein therapeutics in Oncology and Immunology.
  • Previously, he was President and Chief Executive Officer of Ribon Therapeutics, a biopharmaceutical company focused on small molecule drugs for Oncology and Immunology.

Alltrna Announces Presentations at ASGCT 27th Annual Meeting and TIDES USA 2024

Retrieved on: 
월요일, 4월 22, 2024
Computation, Biology, Therapy, Small RNA, Annual general meeting, RNA, Flagship Pioneering, Gene, Cell, Society, Molecular biology

CAMBRIDGE, Mass., April 22, 2024 /PRNewswire/ -- Alltrna , a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced a poster presentation at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting taking place May 7-11 in Baltimore and a talk and two poster presentations at TIDES USA 2024 taking place May 14-17 digitally and in-person in Boston.

Key Points: 
  • CAMBRIDGE, Mass., April 22, 2024 /PRNewswire/ -- Alltrna , a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced a poster presentation at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting taking place May 7-11 in Baltimore and a talk and two poster presentations at TIDES USA 2024 taking place May 14-17 digitally and in-person in Boston.
  • Details of the presentations are as follows:
    Presenter: Stephen Eichhorn, Ph.D., Head of Computational and Molecular Biology, Alltrna